These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11376112)

  • 1. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
    Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
    Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
    Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
    Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
    Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
    Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor.
    Gouédard L; Chen YG; Thevenet L; Racine C; Borie S; Lamarre I; Josso N; Massague J; di Clemente N
    J Biol Chem; 2000 Sep; 275(36):27973-8. PubMed ID: 10854429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMH signaling: from receptor to target gene.
    Visser JA
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):65-73. PubMed ID: 14656478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
    Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Components of the anti-Müllerian hormone signaling pathway in gonads.
    di Clemente N; Josso N; Gouédard L; Belville C
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):9-14. PubMed ID: 14656470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic studies of the AMH/MIS signaling pathway for Müllerian duct regression.
    Jamin SP; Arango NA; Mishina Y; Hanks MC; Behringer RR
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):15-9. PubMed ID: 14656471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mullerian inhibiting substance recruits ALK3 to regulate Leydig cell differentiation.
    Wu X; Zhang N; Lee MM
    Endocrinology; 2012 Oct; 153(10):4929-37. PubMed ID: 22872577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor.
    Renlund N; O'Neill FH; Zhang L; Sidis Y; Teixeira J
    J Endocrinol; 2007 Oct; 195(1):95-103. PubMed ID: 17911401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic cooperation between the beta-catenin signaling pathway and steroidogenic factor 1 in the activation of the Mullerian inhibiting substance type II receptor.
    Hossain A; Saunders GF
    J Biol Chem; 2003 Jul; 278(29):26511-6. PubMed ID: 12724325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of steroidogenesis in Leydig cells by Müllerian-inhibiting substance.
    Fynn-Thompson E; Cheng H; Teixeira J
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):99-104. PubMed ID: 14656482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transduction pathway of anti-Müllerian hormone, a sex-specific member of the TGF-beta family.
    Josso N; Clemente Nd
    Trends Endocrinol Metab; 2003 Mar; 14(2):91-7. PubMed ID: 12591180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic studies of MIS signalling in sexual development.
    Jamin SP; Arango NA; Mishina Y; Behringer RR
    Novartis Found Symp; 2002; 244():157-64; discussion 164-8, 203-6, 253-7. PubMed ID: 11990789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2.
    Macías-Silva M; Hoodless PA; Tang SJ; Buchwald M; Wrana JL
    J Biol Chem; 1998 Oct; 273(40):25628-36. PubMed ID: 9748228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
    Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
    Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.
    Basal E; Ayeni T; Zhang Q; Langstraat C; Donahoe PK; Pepin D; Yin X; Leof E; Cliby W
    Curr Mol Med; 2016; 16(3):222-31. PubMed ID: 26917267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in vivo roles of müllerian-inhibiting substance.
    Behringer RR
    Curr Top Dev Biol; 1994; 29():171-87. PubMed ID: 7828438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of a matrix metalloproteinase in MIS-induced cell death during urogenital development.
    Roberts LM; Visser JA; Ingraham HA
    Development; 2002 Mar; 129(6):1487-96. PubMed ID: 11880357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung.
    Catlin EA; Tonnu VC; Ebb RG; Pacheco BA; Manganaro TF; Ezzell RM; Donahoe PK; Teixeira J
    Endocrinology; 1997 Feb; 138(2):790-6. PubMed ID: 9003016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.